Nav: Home

New research shows which ovarian cancer patients won't benefit from immune-PARP combo

March 19, 2020

BOSTON - In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven't been able to predict which patients won't benefit from the treatment and should explore other options. A new study by Dana-Farber Cancer Institute researchers, is showing that it's now possible to identify such patients in advance.

The study, published online today by Nature Communications, will help investigators testing this combination direct such patients to trials that may have a better chance of helping them.

The study authors found that two factors - a specific pattern of gene mutations in the tumor cells and evidence of a vigorous immune response to the cancer - are markers of whether patients will respond to the combination therapy. Patients whose tumor tissue had either of these features were more likely to have their disease held in check for an extended period of time, whereas those whose tissue lacked either feature showed no benefit from the drug combination.

"By taking these factors into account, researchers leading trials of this combination in patients with advanced, chemotherapy-resistant ovarian cancer may select individuals who may respond to this combination of drugs," says Panagiotis Konstantinopoulos, MD, PhD, director of translational research, Gynecologic Oncology, at Dana-Farber, the co-senior author of the study with Alan D. D'Andrea, MD, director of Dana-Farber's Susan F. Smith Center for Women's Cancers.

While checkpoint inhibitors - which strip tumors of certain protections against an attack by the immune system - work exceptionally well in many types of cancer, ovarian cancer has been an exception. The PD-1 checkpoint inhibitor pembrolizumab, for example, produces responses in less than 5% of patients with PD-L1-negative cancers. The same is true of PARP inhibitors, which undermine cancer cells by reducing their ability to repair DNA damage. As a single agent, the PARP inhibitor niraparib has a beneficial effect in just 3% of patients with ovarian cancer that is resistant to platinum-based chemotherapy and isn't BRCA-mutated.

When checkpoint and PARP inhibitors are used together, however, those benefits multiply. The TOPACIO/Keynote-162 clinical trial led by Konstantinopoulos found that the pembrolizumab-niraparib combination produced complete or partial responses - total or limited shrinkage of ovarian tumors - in 18% of patients with platinum-resistant ovarian cancer. Furthermore, 65% of the study participants had their disease kept under control. For some of those who responded, the benefits lasted for well over a year. The results were especially impressive because all the participants had received multiple previous treatments for ovarian cancer, making them especially hard to treat.

Encouraging as these findings were, study leaders had no way to determine, in advance, which participants wouldn't be helped by the therapy. To see if they could be identified, Konstantinopoulos and his colleagues conducted two analyses of participants' tumor samples: a letter-by-letter search of the tumor cells' genome for abnormalities, and a census of "exhausted" immune system T cells within the tumor tissue. (T cells are said to be exhausted when they are primed to attack tumor cells but fail to do so. Tumors containing large numbers of such T cells can be especially vulnerable to checkpoint-inhibiting drugs.) The researchers then correlated their findings with information on whether, and how extensively, patients responded to the combination therapy.

They found that patients whose tumor cells carried either "mutational signature 3" (a pattern of gene mutations associated with an inability to repair certain kinds of DNA damage) or a "positive immune score" (a measure of signaling activity between tumor cells and the immune system) may derive a benefit from the pembrolizumab-niraparib combination. Patients whose cells lacked either of these features received no such benefit.

"Patients with advanced or metastatic ovarian cancer who are resistant to standard platinum-based chemotherapy agents often have few further options for treatment," Konstantinopoulos remarks. "Our findings will help ensure that patients for whom a PARP inhibitor-checkpoint inhibitor combination won't be beneficial can focus on other clinical trials of treatments that may be more effective for them."
The co-first authors of the study are Anniina Färkkilä, MD, PhD, of Dana-Farber; Doga Gulhan, PhD, of Harvard Medical School; and Julia Casado, MS, of the University of Helsinki. Co-authors are Huy Nguyen, MS, Bose Kochupurakkal, PhD, Dipanjan Chowdhury, PhD, Geoffrey I. Shapiro, MD, PhD, Ursula A. Matulonis, MD, and Peter J. Park, PhD, of Dana-Farber; Connor A. Jacobson, Zoltan Maliga, PhD, Clarence Yapp, DPhil, Yu-An Chen, MS, Denis Schapiro, PhD, and Peter K. Sorger, PhD, of Harvard Medical School; Yinghui Zhou, PhD, Julie R. Graham, PhD, and Bruce J. Dezube, MD, of TESARO, Waltham, Mass.; Pamela Munster, MD, of the Helen Diller Family Comprehensive Cancer Center, San Francisco, Calif.; Sandro Santagata, MD, PhD, Elizabeth Garcia, PhD, Scott Rodig, MD, PhD, and Ana Lako, of Brigham and Women's Hospital; Sampsa Hautaniemi, DTech, of the University of Helsinki; and Elizabeth M. Swisher, MD, of the University of Washington.

The study was supported by a grant from Stand Up to Cancer, the Ovarian Cancer Research Fund, TESARO, GSK Company, and Merck & Co.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is one of the only hospitals ranked in the top five by U.S. News and World Report in both adult and pediatric cancer care. Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

Dana-Farber Cancer Institute

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at